The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated

Key Findings

⚖️ The Weight Comes Back Because Your Fat Cells Remember Being Fat

• A new conceptual framework argues that adipocytes retain persistent epigenetic marks from obesity — a molecular memory that defends a high-body-fat set point even after significant drug-induced weight loss.
• When GLP-1 therapy stops, that defended set point may actively drive regain, independent of willpower or behavior. The authors call this the "Epigenetic Detent."

💊 Oral GLP-1 Drug Shows Dose-Dependent Trade-Offs

• A meta-analysis comparing two maintenance doses of orforglipron — 12 mg versus 36 mg — found the higher dose produced greater weight and metabolic benefits across populations with and without diabetes.
• The higher dose also carried a different safety profile, making the dose choice a genuine clinical trade-off rather than a simple "more is better" decision.

🫀 GLP-1 Drugs Cut Heart Risk Beyond What Weight Loss Explains — Here's a Candidate Mechanism

• The SELECT trial showed semaglutide reduced major cardiovascular events by 20% in people with obesity but without diabetes. Mediation analyses suggested weight loss accounted for roughly one-third of that benefit.
• A new review points to thromboinflammation — specifically the neutrophil-NET axis and platelet function — as a biologically plausible direct mechanism for the remaining two-thirds, though it remains unproven.

🥗 GLP-1 Drugs Cut Fat Mass — But Lean Mass Goes Too

• A meta-analysis of three randomized trials in 171 adults with obesity and without type 2 diabetes found GLP-1 drug users lost significantly more lean mass than controls, alongside greater fat loss.
• The lean mass loss was modest in absolute terms but consistent enough to prompt calls for routine physical activity and nutrition support alongside drug therapy.

🧬 Five-Receptor Drug Combo Outperforms Semaglutide and Tirzepatide in Rats

• Combining retatrutide, a triple incretin receptor agonist, with cagrilintide, an amylin receptor co-agonist, produced greater weight and food intake reductions in obese male rats than either drug alone or combinations including semaglutide or tirzepatide at matched doses.
• Pair-feeding experiments confirmed the extra weight loss wasn't fully explained by eating less — suggesting metabolic effects beyond appetite suppression.

😟 Eating Disorder Screening Should Happen Before Starting GLP-1 Drugs

• A 45-member expert panel using a structured consensus method reached over 91% average agreement that clinicians should screen for current and past eating disorders before prescribing GLP-1 drugs, using a validated instrument.
• The panel recommended generally avoiding these medications in active anorexia, atypical anorexia, and bulimia with significant dietary restraint — and proceeding cautiously even with past histories of these conditions.